PSI met an interim enrollment milestone of 500 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of postoperative nausea and vomiting (PONV).
PSI reached an interim enrollment objective of 100 randomized pediatric patients in a phase III study of a novel antiemetic used for the prevention of chemotherapy-induced nausea and vomiting (CINV).
PSI met an interim enrollment target of 350 randomized patients in a phase III study of a novel biological agent in non-small cell lung cancer (NSCLC).
